The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer.

Autor: Şen GA; Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey. gulinalkan@msn.com., Aydın E; Department of Medical Oncology, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey., Guliyev M; Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey., Öztaş NŞ; Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey., Değerli E; Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey., Demirci NS; Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey., Turna ZH; Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey., Demirelli FH; Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey.

Publikováno v: BMC cancer [BMC Cancer] 2024 Oct 24; Vol. 24 (1), pp. 1311. Date of Electronic Publication: 2024 Oct 24.

The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.

Autor: Yücel KB; Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey., Yekedüz E; Department of Medical Oncology, Faculty of Medicine, Cebeci Hospital, Ankara University, 06590, Cebeci/Ankara, Turkey.; Cancer Research Institute, Ankara University, Ankara, Turkey., Karakaya S; Medical Oncology Department, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey., Tural D; Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey., Ertürk İ; Department of Medical Oncology, Gülhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey., Erol C; Department of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey., Ercelep Ö; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Öztaş NŞ; Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, Istanbul, Turkey., Arslan Ç; Department of Medical Oncology, Faculty of Medicine, İzmir University of Economics, Izmir, Turkey., Uçar G; Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey., Küçükarda A; Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey., Sever ÖN; Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey., Kılıçkap S; Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.; Department of Medical Oncology, Faculty of Medicine, İstinye University, Istanbul, Turkey., Can O; Department of Medical Oncology, Prof. Dr. Cemil Taşçıoğlu City Hospital, University of Health Sciences, Istanbul, Turkey., Yazgan SC; Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey., Öksüzoğlu B; Medical Oncology Department, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey., Karadurmuş N; Department of Medical Oncology, Gülhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey., Şendur MA; Department of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey., Ürün Y; Department of Medical Oncology, Faculty of Medicine, Cebeci Hospital, Ankara University, 06590, Cebeci/Ankara, Turkey. yuksel.urun@ankara.edu.tr.; Cancer Research Institute, Ankara University, Ankara, Turkey. yuksel.urun@ankara.edu.tr.

Publikováno v: Scientific reports [Sci Rep] 2022 Oct 03; Vol. 12 (1), pp. 16559. Date of Electronic Publication: 2022 Oct 03.

Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.

Autor: Yekedüz E; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, 06590, Turkey.; Cancer Research Institute, Ankara University, Ankara, 06590, Turkey., Ertürk İ; Department of Medical Oncology, Gülhane Education & Research Hospital, University of Health Sciences, Ankara, 06010, Turkey., Tural D; Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training & Research Hospital, University of Health Sciences, İstanbul, 34147, Turkey., Karadurmuş N; Department of Medical Oncology, Gülhane Education & Research Hospital, University of Health Sciences, Ankara, 06010, Turkey., Karakaya S; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education & Research Hospital, University of Health Sciences, Ankara, 06200, Turkey., Hızal M; Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, 06800, Turkey., Arıkan R; Department of Medical Oncology, Marmara University, İstanbul, 34899, Turkey., Arslan Ç; Department of Medical Oncology, İzmir University of Economics, İzmir, 35575, Turkey., Taban H; Department of Medical Oncology, Hacettepe University, Ankara, 06230, Turkey., Küçükarda A; Department of Medical Oncology, Trakya University, Edirne, 22020, Turkey., Öztaş NŞ; Division of Medical Oncology, İstanbul University-Cerrahpaşa, İstanbul, 34098, Turkey., Sever ÖN; Department of Medical Oncology, Gaziantep University, Gaziantep, 27070, Turkey., Uçar G; Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, 06800, Turkey., Can O; Department of Medical Oncology, Prof. Dr. Cemil Taşçıoğlu City Hospital, University of Health Sciences, İstanbul, 34384, Turkey., Şendur MA; Department of Medical Oncology, Ankara Yıldırım Beyazıt University, Ankara, 06800, Turkey., Demirci U; Department of Medical Oncology, Üsküdar University, Memorial Ankara Hospital, Ankara, 06520, Turkey., Kılıçkap S; Department of Medical Oncology, Hacettepe University, Ankara, 06230, Turkey.; Department of Medical Oncology, İstinye University, İstanbul, 34010, Turkey., Çiçin İ; Department of Medical Oncology, Trakya University, Edirne, 22020, Turkey., Öksüzoğlu B; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education & Research Hospital, University of Health Sciences, Ankara, 06200, Turkey., Özgüroğlu M; Division of Medical Oncology, İstanbul University-Cerrahpaşa, İstanbul, 34098, Turkey., Ürün Y; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, 06590, Turkey.; Cancer Research Institute, Ankara University, Ankara, 06590, Turkey.

Publikováno v: Future oncology (London, England) [Future Oncol] 2021 Dec; Vol. 17 (35), pp. 4861-4869. Date of Electronic Publication: 2021 Nov 02.